

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.**

## Updated Rule 2.10 Announcement

**Dublin, Ireland – July 17, 2014** – In accordance with Rule 2.10 of The City Code on Takeovers and Mergers, Shire plc (LSE: SHP, NASDAQ: SHPG) confirms that, as at close of business on July 16, 2014, it had in issue 589,401,117 ordinary shares of 5 pence each (excluding ordinary shares held in treasury), with ISIN JE00B2QKY057, which carry voting rights of one vote per share.

Shire plc has an American Depositary Receipt program for which Citibank, N.A. acts as Depositary. One American Depositary Share (“ADS”) represents three ordinary shares of 5 pence each, with ISIN US82481R1068. The ADSs trade on the NASDAQ Global Select Market.

**For further information please contact:**

### Investor Relations

Jeff Poulton  
Sarah Elton-Farr

[jpoulton@shire.com](mailto:jpoulton@shire.com) +1 781 482 0945  
[seltonfarr@shire.com](mailto:seltonfarr@shire.com) +44 1256 894157

### NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

[www.shire.com](http://www.shire.com)